SEHK:2162Biotechs
Can Keymed Biosciences (SEHK:2162) Justify Its Valuation Following The Aeira Licensing Deal?
Keymed Biosciences (SEHK:2162) has moved back into focus after signing an exclusive licensing and commercialization agreement with Aeira that covers its IL-4Ra-targeted antibody Kangyueda across Southeast and Central Asia.
Recent trading has been choppy for Keymed Biosciences. The share price is up 2.60% over the past day to HK$74.95, yet the 7 day and 30 day share price returns are down 4.03% and 4.09%. The 90 day and year to date share price returns of 33.13% and 40.22% point to stronger...